Version 1
: Received: 12 October 2024 / Approved: 14 October 2024 / Online: 14 October 2024 (13:42:24 CEST)
How to cite:
Niv, D.; Anavi, E.; Yaval, L.; Abbas, A.; Rytwo, G.; Gutman, R. Sepiolite–Chitosan–Acetic Acid Biocomposite Attenuates the Development of Obesity and Nonalcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet. Preprints2024, 2024101072. https://doi.org/10.20944/preprints202410.1072.v1
Niv, D.; Anavi, E.; Yaval, L.; Abbas, A.; Rytwo, G.; Gutman, R. Sepiolite–Chitosan–Acetic Acid Biocomposite Attenuates the Development of Obesity and Nonalcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet. Preprints 2024, 2024101072. https://doi.org/10.20944/preprints202410.1072.v1
Niv, D.; Anavi, E.; Yaval, L.; Abbas, A.; Rytwo, G.; Gutman, R. Sepiolite–Chitosan–Acetic Acid Biocomposite Attenuates the Development of Obesity and Nonalcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet. Preprints2024, 2024101072. https://doi.org/10.20944/preprints202410.1072.v1
APA Style
Niv, D., Anavi, E., Yaval, L., Abbas, A., Rytwo, G., & Gutman, R. (2024). Sepiolite–Chitosan–Acetic Acid Biocomposite Attenuates the Development of Obesity and Nonalcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet. Preprints. https://doi.org/10.20944/preprints202410.1072.v1
Chicago/Turabian Style
Niv, D., Giora Rytwo and Roee Gutman. 2024 "Sepiolite–Chitosan–Acetic Acid Biocomposite Attenuates the Development of Obesity and Nonalcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet" Preprints. https://doi.org/10.20944/preprints202410.1072.v1
Abstract
Background/Objectives: Obesity and nonalcoholic fatty liver disease (NAFLD) reduce life expectancy; nonoperative interventions show poor results. Individually, chitosan, acetic acid (AA), and sepiolite clay attenuate high-fat diet-induced obesity (DIO) via reduced energy digestibility and increased energy expenditure. We hypothesized that a chitosan–sepiolite biocomposite suspended in AA would attenuate DIO and NAFLD to a greater extent than AA alone via its more substantial adsorption of nonpolar molecules; Methods: We tested this dietary supplement in C57BL/6J mice fed a high-fat diet, compared to supplementation of a bile-acid sequestrant (cholestyramine) and standalone AA; Results: Biocomposite supplementation attenuated DIO rate and NAFLD progression, whereas standalone AA showed mild attenuation of DIO gain and did not prevent HFD-induced hepatic fat accumulation. Biocomposite intake was accompanied by a decreasing digestibility trend counterbalanced by increased intake; hence, it did not affect energy absorption; Conclusions: Therefore, DIO attenuation was suggested to be related to higher energy expenditure, a phenomenon not found with AA alone, as supported by calculated energy expenditure using the energy-balance method. These results support further investigation of the biocomposite’s efficacy in attenuating obesity and NAFLD, specifically when applied with a restricted diet. Future studies are needed to determine this biocomposite's safety, mechanism of action, and efficacy compared to its components given separately or combined with other ingredients.
Biology and Life Sciences, Endocrinology and Metabolism
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
